Assignee
NEUROPORE THERAPIES INC
US·11 granted patents·8 pending applications·18 citations·filing 2013–2024
Top patents by PatentIndex Score
19 records- 0192US12049462B2Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathwaysNEUROPORE THERAPIES INC·Filed 2022·Granted Jul 30, 2024·1 cites·34 claims
- 0289US11492348B2Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathwaysNEUROPORE THERAPIES INC·Filed 2019·Granted Nov 8, 2022·3 cites·17 claims
- 0389US11008294B2Substituted phenyl sulfonyl phenyl triazole thiones and uses thereofNEUROPORE THERAPIES INC·Filed 2019·Granted May 18, 2021·3 cites·22 claims
- 0487US10501423B2Substituted phenyl sulfonyl phenyl triazole thiones and uses thereofNEUROPORE THERAPIES INC·Filed 2019·Granted Dec 10, 2019·3 cites·23 claims
- 0586US11708338B2Substituted phenyl sulfonyl phenyl triazole thiones and uses thereofNEUROPORE THERAPIES INC·Filed 2021·Granted Jul 25, 2023·1 cites·24 claims
- 0683US9284309B2Di- and tri-heteroaryl derivatives as inhibitors of protein aggregationNEUROPORE THERAPIES INC·Filed 2013·Granted Mar 15, 2016·6 cites·20 claims
- 0781US2024327396A1Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathwaysNEUROPORE THERAPIES INC·Filed 2024·Application pending·0 cites
- 0879US2023391734A1Substituted phenyl sulfonyl phenyl triazole thiones and uses thereofNEUROPORE THERAPIES INC·Filed 2023·Application pending·0 cites
- 0975US11236079B2Morpholine derivates as inhibitors of Vps34NEUROPORE THERAPIES INC·Filed 2019·Granted Feb 1, 2022·1 cites·34 claims
- 1073US2022396583A1Compounds as modulators of tlr2 signalingNEUROPORE THERAPIES INC·Filed 2022·Application pending·0 cites
- 1172US2022298155A1Compounds and compositions as modulators of tlr signalingNEUROPORE THERAPIES INC·Filed 2022·Application pending·0 cites
- 1268US11345713B2Compounds as modulators of TLR2 signalingNEUROPORE THERAPIES INC·Filed 2019·Granted May 31, 2022·0 cites·16 claims
- 1361US11299487B2Compounds and compositions as modulators of TLR signalingNEUROPORE THERAPIES INC·Filed 2020·Granted Apr 12, 2022·0 cites·8 claims
- 1456US9738635B2Heteroaryl amides as inhibitors of protein aggregationNEUROPORE THERAPIES INC·Filed 2015·Granted Aug 22, 2017·0 cites·6 claims
- 1556US2024043395A1Compounds and compositions as modulators of tlr signalingNEUROPORE THERAPIES INC·Filed 2021·Application pending·0 cites
- 1651US2014364610A1Compound suitable for the treatment of synucleopathiesNEUROPORE THERAPIES INC·Filed 2014·Application pending·0 cites
- 1744US9527852B2Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregationNEUROPORE THERAPIES INC·Filed 2013·Granted Dec 27, 2016·0 cites·18 claims
- 1843US2015197513A1Aryl- and heteroaryl-substituted benzene derivatives as modulators of pi3-kinase signalling pathwaysNEUROPORE THERAPIES INC·Filed 2013·Application pending·0 cites
- 1941US2021290597A1Method of treating a condition associated with neurodegeneration using inhibitors of oat3NEUROPORE THERAPIES INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when NEUROPORE THERAPIES INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →